Expression levels of IL-27 and IL-17 in multiple myeloma patients: A higher ratio of IL-27:IL-17 in bone marrow was associated with a superior progression-free survival

Leukemia Research

Volumn 37, Issue 9, 2013, Pages 1094-1099

  Song, Xiao Ning ^a   Yang, Jian Zhu ^a   Sun, Li Xia ^a   Meng, Jian Bo ^a   Zhang, Jin Qiao ^a   Lv, Hong Yan ^a   Kong, Ling Juan ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

Interleukin 17; Interleukin 27; Multiple myeloma; Progression free survival

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 27;

ADULT; ARTICLE; BONE MARROW; CANCER GROWTH; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION;

INTERLEUKIN-17; INTERLEUKIN-27; MULTIPLE MYELOMA; PROGRESSION-FREE SURVIVAL;

BONE MARROW; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERLEUKIN-17; INTERLEUKINS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM STAGING; PROGNOSIS; REMISSION INDUCTION; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84880960857     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.06.022     Document Type: Article

References (33)

1. Durie B.G., Harousseau J.L., Miguel J.S., Blade J., Barlogie B., Anderson K., et al. International uniform response criteria for multiple myeloma. Leukemia 2006, 20:1467-1473.
2. Roodman G.D. Role of the bone marrow microenvironment in multiple myeloma. J Bone Miner Res 2002, 17:1921-1925.
3. Kawano M., Hirano T., Matsuda T., Taga T., Horii Y., Iwato K., et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 1988, 332:83-85.
4. Podar K., Anderson K.C. The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood 2005, 105:1383-1395.
5. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008, 8:915-928.
6. Su X., Ye J., Hsueh E.C., Zhang Y., Hoft D.F., Peng G. Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J Immunol 2010, 184:1630-1641.
7. Yang L., Qi Y., Hu J., Tang L., Zhao S., Shan B. Expression of Th17 cells in breast cancer tissue and its association with clinical parameters. Cell Biochem Biophys 2012, 62:153-159.
8. Prabhala R.H., Pelluru D., Fulciniti M., Prabhala H.K., Nanjappa P., Song W., et al. Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood 2010, 115:5385-5392.
9. Alexandrakis M.G., Pappa C.A., Miyakis S., Sfiridaki A., Kafousi M., Alegakis A., et al. Serum interleukin-17 and its relationship to angiogenic factors in multiple myeloma. Eur J Intern Med 2006, 17:412-416.
10. Scudla V., Budikova M., Petrova P., Minarik J., Pika T., Bacovsky J., et al. Ceska myelomova s: analysis of serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and multiple myeloma. Klinicka onkologie: casopis Ceske a Slovenske onkologicke spolecnosti 2010, 23:171-181.
11. Noonan K., Marchionni L., Anderson J., Pardoll D., Roodman G.D., Borrello I. A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma. Blood 2010, 116:3554-3563.
12. Pflanz S., Timans J.C., Cheung J., Rosales R., Kanzler H., Gilbert J., et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity 2002, 16:779-790.
13. Yoshida H., Hamano S., Senaldi G., Covey T., Faggioni R., Mu S., et al. WSX-1 is required for the initiation of Th1 responses and resistance to L. major infection. Immunity 2001, 15:569-578.
14. Pflanz S., Hibbert L., Mattson J., Rosales R., Vaisberg E., Bazan J.F., et al. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J Immunol 2004, 172:2225-2231.
15. Hunter C.A. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat Rev Immunol 2005, 5:521-531.
16. Murugaiyan G., Mittal A., Lopez-Diego R., Maier L.M., Anderson D.E., Weiner H.L. IL-27 is a key regulator of IL-10 and IL-17 production by human CD4+ T cells. J Immunol 2009, 183:2435-2443.
17. Batten M., Li J., Yi S., Kljavin N.M., Danilenko D.M., Lucas S., et al. Interleukin 27 limits autoimmune encephalomyelitis by suppressing the development of interleukin 17-producing T cells. Nat Immunol 2006, 7:929-936.
18. Stumhofer J.S., Laurence A., Wilson E.H., Huang E., Tato C.M., Johnson L.M., et al. Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system. Nat Immunol 2006, 7:937-945.
19. Ouaked N., Mantel P.Y., Bassin C., Burgler S., Siegmund K., Akdis C.A., et al. Regulation of the foxp3 gene by the Th1 cytokines: the role of IL-27-induced STAT1. J Immunol 2009, 182:1041-1049.
20. Amadi-Obi A., Yu C.R., Liu X., Mahdi R.M., Clarke G.L., Nussenblatt R.B., et al. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat Med 2007, 13:711-718.
21. Colgan J., Rothman P. All in the family: IL-27 suppression of T(H)-17 cells. Nat Immunol 2006, 7:899-901.
22. Hisada M., Kamiya S., Fujita K., Belladonna M.L., Aoki T., Koyanagi Y., et al. Potent antitumor activity of interleukin-27. Cancer Res 2004, 64:1152-1156.
23. Oniki S., Nagai H., Horikawa T., Furukawa J., Belladonna M.L., Yoshimoto T., et al. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma. Cancer Res 2006, 66:6395-6404.
24. Cocco C., Giuliani N., Di Carlo E., Ognio E., Storti P., Abeltino M., et al. Interleukin-27 acts as multifunctional antitumor agent in multiple myeloma. Clin Cancer Res 2010, 16:4188-4197.
25. Oteri G., Allegra A., Bellomo G., Alonci A., Nastro E., Penna G., et al. Reduced serum levels of Interleukin 17 in patients with osteonecrosis of the jaw and in multiple myeloma subjects after bisphosphonates administration. Cytokine 2008, 43:103-104.
26. Airoldi I., Di Carlo E., Banelli B., Moserle L., Cocco C., Pezzolo A., et al. The IL-12Rbeta2 gene functions as a tumor suppressor in human B cell malignancies. J Clin Investig 2004, 113:1651-1659.
27. Salcedo R., Hixon J.A., Stauffer J.K., Jalah R., Brooks A.D., Khan T., et al. Immunologic and therapeutic synergy of IL-27 and IL-2: enhancement of T cell sensitization, tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow. J Immunol 2009, 182:4328-4338.
28. Shimizu M., Shimamura M., Owaki T., Asakawa M., Fujita K., Kudo M., et al. Antiangiogenic and antitumor activities of IL-27. J Immunol 2006, 176:7317-7324.
29. Yoshimoto T., Morishima N., Mizoguchi I., Shimizu M., Nagai H., Oniki S., et al. Antiproliferative activity of IL-27 on melanoma. J Immunol 2008, 180:6527-6535.
30. Ho M.Y., Leu S.J., Sun G.H., Tao M.H., Tang S.J., Sun K.H. IL-27 directly restrains lung tumorigenicity by suppressing cyclooxygenase-2-mediated activities. J Immunol 2009, 183:6217-6226.
31. Matsui M., Kishida T., Nakano H., Yoshimoto K., Shin-Ya M., Shimada T., et al. Interleukin-27 activates natural killer cells and suppresses NK-resistant head and neck squamous cell carcinoma through inducing antibody-dependent cellular cytotoxicity. Cancer Res 2009, 69:2523-2530.
32. Trinchieri G., Pflanz S., Kastelein R.A. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity 2003, 19:641-644.
33. Xu M., Mizoguchi I., Morishima N., Chiba Y., Mizuguchi J., Yoshimoto T. Regulation of antitumor immune responses by the IL-12 family cytokines, IL-12, IL-23, and IL-27. Clin Dev Immunol 2010, 2010:1-9.